BRCA2 and neoplasm: To investigate RNASEH2B and RB1 genomic loss, chromosome 13 deletions were evaluated in circulating tumor DNA (ctDNA) low-pass whole genome sequencing (lpWGS) from patients with mCRPC before treatment with taxanes (n = 267), demonstrating that shallow deletions encompassing both RB1 and RNASEH2B are common (present in 52% of the samples), and sometimes involve BRCA2, with deep deletions occurring infrequently (2% of the samples, Figure 1B).